Ocular Therapeutix Inc.
OCUL | NASDAQ
$10.50
+$0.51 (+5.11%)
At close: Sep 22, 2026, 4:00 PM ET
$10.45
-$0.05 (-0.48%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Pravin U. Dugel | Executive Chairman, President & Chief Executive Officer |
| Donald Notman Jr. | Chief Operating Officer (Leave of Absence) |
| Todd Anderman | Chief Legal Officer & Corporate Secretary |
| Jason Robins | CFO & Principal Accounting Officer |
| Jeffrey S. Heier | Chief Scientific Officer |
| Nadia K. Waheed | Chief Medical Officer |
| Peter K. Jarrett | Chief Technical Officer |
| Sanjay Nayak MBBS | Chief Strategy Officer |
| Steve Meyers | Chief Commercial Officer |
| William S. Slattery Jr. | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 03, 2026 | S-8 | Filing |
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 18, 2026 | 4 | Filing |
Ocular Therapeutix Inc.
| Country | United States |
| IPO Date | Jul 24, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 325 |
| CEO | Pravin U. Dugel |
Contact Details
24 Crosby Drive Bedford,
Massachusetts 01730 United States
Stock Details
| Ticker Symbol | OCUL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001393434 |
| CUSIP Number | 67576A100 |
| ISIN Number | US67576A1007 |
| SIC Code | 2834 |
Recent News
- 23 days ago / globenewswire.comOcular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
- 1 month ago / seekingalpha.comOcular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
- 1 month ago / benzinga.comWhy Is Ocular Therapeutix Stock Gaining Monday?
- 2 months ago / zacks.comOcular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
- 2 months ago / globenewswire.comOcular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
- 2 months ago / marketbeat.comOcular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
- 3 months ago / globenewswire.comOcular Therapeutix™ to Participate in July Scientific and Investor Conferences
- 3 months ago / seekingalpha.comOcular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
- 3 months ago / benzinga.comOcular Therapeutix Maps Regulatory Strategy For Lead Drug Program
- 3 months ago / fool.comOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Add to Watchlist
Select watchlists to add or remove OCUL